Clinical trials have used various doses and treatment ... The dose administered to patients with CLL in the phase 3 trial was 100 mg/m 2 daily on 2 consecutive days every 28 days ( Table 1).
the available clinical data shed little light on its role in the treatment of CLL. Adverse effects include myelosuppression and gastrointestinal complaints. In a recent phase III trial of ...
The German CLL Study Group conducted a randomized, double-blind, placebo-controlled phase III trial with 363 patients with asymptomatic ... expressed in this Data Supplement do not necessarily reflect ...
Erratum: ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma The German CLL Study Group conducted a ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
If you’ve received a CLL diagnosis, you may want to consider participating in a clinical trial. CLL progression and severity can vary significantly from person to person, and clinical trials ...
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, as a booster vaccine for patients with chronic lymphocytic leukemia (CLL).
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...